NO20042209L - Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner - Google Patents

Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner

Info

Publication number: NO20042209L
Authority: NO; Norway
Prior art keywords: translational modifications; post; mammalian cells; predetermined post; present
Prior art date: 2001-10-29

Application number

NO20042209A

Other languages

English (en)

Inventor

Abraham Bout

Johan Christiaan Kapteyn

Petrus Christianus Joh Passier

Ronald Hendrik Peter Brus

Dirk Jan Elbertus Opstelten

Original Assignee

Crucell Holland Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-29

Filing date

2004-05-28

Publication date

2004-07-28

2001-10-29 Priority claimed from PCT/NL2001/000792 external-priority patent/WO2003050286A1/en

2002-04-19 Priority claimed from PCT/NL2002/000257 external-priority patent/WO2003089468A1/en

2004-05-28 Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv

2004-07-28 Publication of NO20042209L publication Critical patent/NO20042209L/no

Links

230000004481 post-translational protein modification Effects 0.000 title abstract 6
238000000034 method Methods 0.000 title abstract 4
102000004169 proteins and genes Human genes 0.000 title abstract 3
108090000623 proteins and genes Proteins 0.000 title abstract 3
210000004962 mammalian cell Anatomy 0.000 abstract 5
102000003951 Erythropoietin Human genes 0.000 abstract 3
108090000394 Erythropoietin Proteins 0.000 abstract 3
229940105423 erythropoietin Drugs 0.000 abstract 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 3
230000013595 glycosylation Effects 0.000 abstract 2
238000006206 glycosylation reaction Methods 0.000 abstract 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
229920001542 oligosaccharide Polymers 0.000 abstract 1
150000002482 oligosaccharides Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Wood Science & Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)

NO20042209A 2001-10-29 2004-05-28 Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner NO20042209L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/NL2001/000792 WO2003050286A1 (en)	2001-10-29	2001-10-29	Methods and means for producing proteins with predetermined post-translational modifications
PCT/NL2002/000257 WO2003089468A1 (en)	2002-04-19	2002-04-19	Methods and means for producing proteins with predetermined post-translational modifications
PCT/NL2002/000686 WO2003038100A1 (en)	2001-10-29	2002-10-29	Methods and means for producing proteins with predetermined post-translational modifications

Publications (1)

Publication Number	Publication Date
NO20042209L true NO20042209L (no)	2004-07-28

Family

ID=26642018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042209A NO20042209L (no)	2001-10-29	2004-05-28	Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner

Country Status (14)

Country	Link
US (3)	US7304031B2 (no)
EP (2)	EP1440157B1 (no)
JP (1)	JP4583029B2 (no)
CN (1)	CN100347306C (no)
AT (1)	ATE542904T1 (no)
AU (1)	AU2002335585B2 (no)
BR (1)	BR0213402A (no)
CA (2)	CA2756610C (no)
DK (1)	DK1440157T3 (no)
EA (2)	EA008220B1 (no)
ES (1)	ES2381104T3 (no)
IL (3)	IL161674A (no)
NO (1)	NO20042209L (no)
WO (1)	WO2003038100A1 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI0833934T2 (sl)	1995-06-15	2013-04-30	Crucell Holland B.V.	Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US6855544B1 (en)	1999-04-15	2005-02-15	Crucell Holland B.V.	Recombinant protein production in a human cell
US7297680B2 (en)	1999-04-15	2007-11-20	Crucell Holland B.V.	Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050164386A1 (en) *	1999-04-15	2005-07-28	Uytdehaag Alphonsus G.	Overexpression of enzymes involved in post-translational protein modifications in human cells
US8236561B2 (en)	1999-04-15	2012-08-07	Crucell Holland B.V.	Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en)	1999-04-15	2009-10-20	Crucell Holland B.V.	Transient protein expression methods
US7192759B1 (en)	1999-11-26	2007-03-20	Crucell Holland B.V.	Production of vaccines
US7521220B2 (en)	1999-11-26	2009-04-21	Crucell Holland B.V.	Production of vaccines
US7527961B2 (en)	1999-11-26	2009-05-05	Crucell Holland B.V.	Production of vaccines
US20030072737A1 (en)	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en)	2000-12-29	2010-08-03	The Kenneth S. Warren Institute, Inc.	Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
CA2756610C (en) *	2001-10-29	2015-08-25	Crucell Holland B.V.	Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
KR100979025B1 (ko)	2001-12-07	2010-08-30	크루셀 홀란드 비.브이.	바이러스, 바이러스 단리물 및 백신의 생산
US8524477B2 (en)	2002-10-29	2013-09-03	Crucell Holland B.V.	Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
WO2005090390A1 (en) *	2004-03-17	2005-09-29	Crucell Holland B.V.	Novel assay for the separation and quantification of hemagglutinin antigens
JP2008527980A (ja) *	2005-01-25	2008-07-31	アポロライフサイエンシズリミテッド	分子およびそのキメラ分子
US20100040581A1 (en) *	2005-06-01	2010-02-18	Niigata Tlo Corporation	Epo derivative-containing therapeutic agents for blood-related diseases
AR053416A1 (es) *	2005-11-10	2007-05-09	Protech Pharma S A	Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
EP1954815B1 (en) *	2005-11-15	2015-02-25	GlycoFi, Inc.	Production of glycoproteins with reduced o-glycosylation
US7642078B2 (en)	2005-12-28	2010-01-05	Crucell Holland B.V.	Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US10351615B2 (en)	2006-02-03	2019-07-16	Opko Biologics Ltd.	Methods of treatment with long-acting growth hormone
US20140113860A1 (en)	2006-02-03	2014-04-24	Prolor Biotech Ltd.	Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en)	2006-02-03	2016-02-02	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
US10221228B2 (en)	2006-02-03	2019-03-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en)	2006-02-03	2015-02-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US7553941B2 (en) *	2006-02-03	2009-06-30	Modigene Inc	Long-acting polypeptides and methods of producing same
US8048849B2 (en)	2006-02-03	2011-11-01	Modigene, Inc.	Long-acting polypeptides and methods of producing same
US8946155B2 (en)	2006-02-03	2015-02-03	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
WO2007098548A1 (en) *	2006-03-01	2007-09-07	Apollo Life Sciences Limited	A molecule and chimeric molecules thereof
AR061269A1 (es)	2006-06-07	2008-08-13	Chugai Pharmaceutical Co Ltd	Composicion y metodo de revascularizacion para el tratamiento de enfermedades isquemicas usando eritropoyetina
CN101505788B (zh)	2006-08-22	2013-06-26	中外制药株式会社	周围神经病变的预防和/或治疗药
AR065613A1 (es)	2007-03-09	2009-06-17	Chugai Pharmaceutical Co Ltd	Agentes de proteccion para organos transplantados
BRPI0810065A2 (pt)	2007-04-16	2020-01-14	Momenta Pharmaceuticals, Inc.	caracterização de n-glicanos usando exoglicosidases
TWI488640B (zh)	2008-04-16	2015-06-21	菲瑞茵國際中心股份有限公司	藥學製劑
US8138092B2 (en)	2009-01-09	2012-03-20	Lam Research Corporation	Spacer formation for array double patterning
US9663778B2 (en)	2009-07-09	2017-05-30	OPKO Biologies Ltd.	Long-acting coagulation factors and methods of producing same
US12203113B2 (en)	2009-07-09	2025-01-21	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
TWI532495B (zh) *	2009-10-05	2016-05-11	菲瑞茵國際中心股份有限公司	藥學製劑
US9757469B2 (en)	2011-03-31	2017-09-12	Ferring B.V.	Pharmaceutical preparation
EP2773964A4 (en) *	2011-11-03	2015-06-24	Stc Biolog Inc	METHOD FOR DETERMINING THE PHARMACOLOGICAL PROPERTIES OF RECOMBINANT PROTEINS
BR112014025951A2 (pt)	2012-04-19	2017-07-11	Opko Biologics Ltd	variantes de oxintomodulina de longa ação e métodos de produção do mesmo
US9790268B2 (en)	2012-09-12	2017-10-17	Genzyme Corporation	Fc containing polypeptides with altered glycosylation and reduced effector function
EA033788B1 (ru)	2012-11-20	2019-11-26	Opko Biologics Ltd	Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
CN110256560A (zh)	2013-03-11	2019-09-20	建新公司	通过糖工程的位点特异性抗体-药物偶联
US20150158926A1 (en)	2013-10-21	2015-06-11	Opko Biologics, Ltd.	Long-acting polypeptides and methods of producing and administering same
US20180180626A1 (en) *	2014-07-01	2018-06-28	Stc Biologics, Inc.	A method for development of recombinant proteins with fingerprint like similarity to the reference product
HRP20230405T8 (hr)	2014-12-10	2023-09-29	Opko Biologics Ltd.	Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta
ES2893616T3 (es)	2015-06-19	2022-02-09	Opko Biologics Ltd	Factores de coagulación de acción prolongada y métodos para la producción de los mismos
MY206271A (en)	2016-07-11	2024-12-06	Opko Biologics Ltd	Long-acting coagulation factor vii and methods of producing same
AU2017297767B2 (en) *	2016-07-12	2021-09-09	Hexal Ag	Glycoprotein with reduced acetylation rate of sialic acid residues
WO2018182529A1 (en) *	2017-03-29	2018-10-04	Agency For Science, Technology And Research	Anti oligosaccharide antibody
WO2019075053A1 (en) *	2017-10-11	2019-04-18	Elanco Us Inc.	PORCINE G-CSF VARIANTS AND USES THEREOF
CN111514279B (zh) *	2020-06-16	2023-07-18	温州医科大学附属第二医院（温州医科大学附属育英儿童医院）	神经营养因子3在制备治疗男性性腺功能减退症的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU646822B2 (en)	1989-10-13	1994-03-10	Kirin-Amgen Inc.	Erythropoietin isoforms
US5789247A (en) *	1994-04-01	1998-08-04	Ballay; Annick	Expression in non-tumoral human lymphoblastoid lines with an integrative vector
SI0833934T2 (sl)	1995-06-15	2013-04-30	Crucell Holland B.V.	Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US6783980B2 (en)	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
ATE290091T1 (de) *	1997-03-27	2005-03-15	Univ British Columbia	Insekten-expressionsvektoren
CA2221819A1 (en)	1997-03-27	1998-09-27	Thomas A. Gigliatti	Insect expression vectors
US6929946B1 (en)	1998-11-20	2005-08-16	Crucell Holland B.V.	Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
AU784550B2 (en)	1999-04-13	2006-05-04	Kenneth S. Warren Institute, Inc., The	Modulation of excitable tissue function by peripherally administered erythropoietin
US20050164386A1 (en)	1999-04-15	2005-07-28	Uytdehaag Alphonsus G.	Overexpression of enzymes involved in post-translational protein modifications in human cells
US6855544B1 (en)	1999-04-15	2005-02-15	Crucell Holland B.V.	Recombinant protein production in a human cell
US7297680B2 (en)	1999-04-15	2007-11-20	Crucell Holland B.V.	Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CN100457914C (zh) *	1999-04-15	2009-02-04	荷兰克鲁塞尔公司	用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
US6913922B1 (en)	1999-05-18	2005-07-05	Crucell Holland B.V.	Serotype of adenovirus and uses thereof
FI109811B (fi) *	2000-09-26	2002-10-15	Medicel Oy	Menetelmä GDP-L-fukoosin valmistamiseksi ja menetelmässä käytettäviä välineitä
DE10056136A1 (de)	2000-11-07	2002-05-16	Nemod New Modalities	Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
US7473767B2 (en)	2001-07-03	2009-01-06	The Institute For Systems Biology	Methods for detection and quantification of analytes in complex mixtures
EP2042196B1 (en) *	2001-10-10	2016-07-13	ratiopharm GmbH	Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
CA2756610C (en)	2001-10-29	2015-08-25	Crucell Holland B.V.	Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
NZ537277A (en)	2002-07-18	2008-04-30	Crucell Holland Bv	Recombinant production of mixtures of antibodies
WO2005090390A1 (en)	2004-03-17	2005-09-29	Crucell Holland B.V.	Novel assay for the separation and quantification of hemagglutinin antigens
US7183371B2 (en) *	2004-11-01	2007-02-27	General Electric Company	Method for making polycarbonate
US20080139608A1 (en)	2006-12-06	2008-06-12	Universiteit Leiden	2,6,8, Trisubstituted 1-deazapurines and their different uses

2002
- 2002-10-29 CA CA2756610A patent/CA2756610C/en not_active Expired - Fee Related
- 2002-10-29 CA CA2465007A patent/CA2465007C/en not_active Expired - Fee Related
- 2002-10-29 JP JP2003540365A patent/JP4583029B2/ja not_active Expired - Fee Related
- 2002-10-29 WO PCT/NL2002/000686 patent/WO2003038100A1/en not_active Ceased
- 2002-10-29 EA EA200400605A patent/EA008220B1/ru not_active IP Right Cessation
- 2002-10-29 ES ES02770322T patent/ES2381104T3/es not_active Expired - Lifetime
- 2002-10-29 EP EP02770322A patent/EP1440157B1/en not_active Expired - Lifetime
- 2002-10-29 EA EA200602163A patent/EA012340B1/ru not_active IP Right Cessation
- 2002-10-29 CN CNB028216903A patent/CN100347306C/zh not_active Expired - Fee Related
- 2002-10-29 US US10/494,140 patent/US7304031B2/en not_active Expired - Fee Related
- 2002-10-29 EP EP10177590.6A patent/EP2292770B1/en not_active Expired - Lifetime
- 2002-10-29 AT AT02770322T patent/ATE542904T1/de active
- 2002-10-29 BR BR0213402-0A patent/BR0213402A/pt not_active IP Right Cessation
- 2002-10-29 AU AU2002335585A patent/AU2002335585B2/en not_active Ceased
- 2002-10-29 DK DK02770322.2T patent/DK1440157T3/da active
2004
- 2004-04-29 IL IL161674A patent/IL161674A/en not_active IP Right Cessation
- 2004-05-28 NO NO20042209A patent/NO20042209L/no not_active Application Discontinuation
2007
- 2007-01-24 US US11/657,202 patent/US7785833B2/en not_active Expired - Fee Related
- 2007-08-01 US US11/888,776 patent/US7696157B2/en not_active Expired - Fee Related
2009
- 2009-10-21 IL IL201673A patent/IL201673A/en not_active IP Right Cessation
- 2009-10-21 IL IL201674A patent/IL201674A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP4583029B2 (ja)	2010-11-17
WO2003038100A1 (en)	2003-05-08
EA200602163A1 (ru)	2007-04-27
EP2292770B1 (en)	2014-11-26
EP1440157B1 (en)	2012-01-25
EA012340B1 (ru)	2009-10-30
IL201673A (en)	2013-10-31
CN1578838A (zh)	2005-02-09
IL161674A (en)	2014-06-30
ES2381104T3 (es)	2012-05-23
US20050164917A1 (en)	2005-07-28
US7304031B2 (en)	2007-12-04
CA2756610A1 (en)	2003-05-08
US7785833B2 (en)	2010-08-31
ATE542904T1 (de)	2012-02-15
CN100347306C (zh)	2007-11-07
EA008220B1 (ru)	2007-04-27
EP2292770A3 (en)	2012-12-19
US7696157B2 (en)	2010-04-13
BR0213402A (pt)	2004-10-13
EP1440157A1 (en)	2004-07-28
JP2005507426A (ja)	2005-03-17
US20070117742A1 (en)	2007-05-24
EA200400605A1 (ru)	2004-08-26
DK1440157T3 (da)	2012-05-07
CA2465007A1 (en)	2003-05-08
IL201674A (en)	2013-10-31
CA2465007C (en)	2012-01-17
US20080032922A1 (en)	2008-02-07
CA2756610C (en)	2015-08-25
AU2002335585B2 (en)	2007-08-16
EP2292770A2 (en)	2011-03-09

Legal Events

Date	Code	Title	Description
2013-07-15	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20042209L (no)	2004-07-28	Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner
DE59608743D1 (de)	2002-03-21	Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation
DE69434578D1 (de)	2006-01-26	Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteine in Zellen von Säugertieren
ATE119198T1 (de)	1995-03-15	Verfahren zur herstellung von proteinen mittels rekombinanter dna.
ATE278024T1 (de)	2004-10-15	Methode zur herstellung von rekombinanten zellen
DE69938867D1 (de)	2008-07-17	Verfahren und verwendung von anordungen von proteinfixierungsmitteln
ATE91716T1 (de)	1993-08-15	Verfahren zur herstellung vielkettige polypeptide oder proteine.
NO911688L (no)	1991-05-31	Neurotrophin-3, en ny neurotrofisk faktor relatert til neurovekstfaktor og hjerne-avledet neurotrofisk faktor.
ATE500331T1 (de)	2011-03-15	Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
DK1218509T3 (da)	2009-07-27	Fibroblast vækstfaktorlignende polypeptider
DE69029657D1 (de)	1997-02-20	Menschliches cytokin, interleukin-9
KR910004803A (ko)	1991-03-29	간의 실질 세포 성장 인자, 이를 코딩하는 유전자, 이 인자를 생산하는 방법, 및 이 인자를 생산하는 형질전환체
ATE289354T1 (de)	2005-03-15	Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen.
DK1042461T3 (da)	2007-09-24	Ekspressionskloning i filiforme svampe
ATE438722T1 (de)	2009-08-15	Verfahren zur herstellung von proteinen unter reduktion von mannosephosphat in der zuckerkette und dadurch hergestelltes glykoprotein
ATE397061T1 (de)	2008-06-15	Verfahren zur herstellung von proteinen
ATE424410T1 (de)	2009-03-15	Interleukin-19.
ATE433486T1 (de)	2009-06-15	Durchmusterung von bibliotheken exprimierter dna in filamentösen pilzen mit hoher durchsatzrate
PT1025245E (pt)	2006-08-31	Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
ATE328102T1 (de)	2006-06-15	Verfahren zur herstellung von proteine
ATE220714T1 (de)	2002-08-15	Verfahren zur herstellung von proteinen
DE60222405D1 (de)	2007-10-25	Verfahren zur verbesserung von proteinprodukten
ATE435277T1 (de)	2009-07-15	18477, eine menschliche proteinkinase und deren verwendung
ATE196165T1 (de)	2000-09-15	Methoden zur herstellung von protein c
DK0708831T4 (da)	2008-04-14	Celledensitetsforstærkede proteintyrosinphosphataser